Hodgkin Lymphoma (HL) patients who have relapsed or progressed following autologous hematopoietic stem cell transplantation (ASCT) have poor prognosis. The efficacy of salvage radiotherapy (RT) in terms of local control and survival was analyzed through a chart review. Among 347 patients with recurrent/refractory HL who received ASCT from 1986–2006, 163 had post-ASCT progression or relapse. Of those, 56 received salvage RT (n = 56) and form the basis of this report. The male:female ratio was 1.3:1. Median age at salvage RT was 32 years (range,19.4–61.6). Nodular sclerosis accounted for 84%. Previous RT had been given in 33 patients (59%). Disease was confined to lymph nodes in 32 patients while 24 had both nodal and extranodal disease (most frequently in bone, 18/24 patients). Mediastinal disease was present in 22 (39%). The RT alone was given in 34 patients (61%), while RT and chemotherapy was given in 22 (39%). Median interval from AS chemotherapy to relapse was 0.51 years (range, 0.1–5.5) and from AS chemotherapy to salvage RT was 0.8 years (range, 0.1–5.6). All the involved sites were radiated in 39 patients (70%) while 17 (30%) were radiated at symptomatic sites only. The median RT dose was 35 Gy (range, 8–40.3), and 46 patients (85%) received 30–40 Gy. The RT technique was extended field in 20 patients (36%), and involved field in 36 (64%). Survival was calculated from the start date of salvage RT. Disease progression in the RT volume was regarded as local failure, while progression outside RT volume was judged as systemic failure. The median follow-up from salvage RT was 31.3 months (range, 0.2–205.5). The overall response rate to RT was 84% (CR, 36%; PR, 48%; SD, 11%). The median overall survival (OS) was 40.8 month (95% CI, 34.2–56.3). The 5-year OS was 32% (95% CI, 17–49). The 2-year PFS was 16% (95% CI, 8–27), the 2-year local PFS was 69% (95% CI, 57–81), while the 2-year systemic PFS was 17% (95% CI, 0.09–0.31). Five patients (9%) had long-term disease-free survival at 4.4, 5.3, 6.3, 6.4, and 17.1 years. Of these 5 patients, 3 were in continuous CR following salvage RT, while 2 had relapsed after RT and received further treatment (1 with second course RT, another with RT+chemotherapy), but both >5 years beyond last treatment, disease free. At last follow-up, 36 patients had died (22 with systemic disease progression, 11 with both systemic and local progression of disease, and 3 had died due to causes other than HL). Among 20 alive patients, 9 had systemic disease progression, 5 had both systemic and local progression, 1 had local progression alone, and 5 were disease free. The RT results in high rates of local disease control in chemorefractory HL. However, patients who fail ASCT have a poor prognosis with a very high probability of systemic disease progression. In selected cases, RT provides a local control rate of 70% at 2 years, and occasionally leads to long-term survival.